News

UroToday2h
ASCO 2025: Antibody-Drug Conjugates in Urothelial Carcinoma: Bridging Innovation and Community Practice
Annual Meeting held in Chicago, IL, was host to a State of the Science session on novel diagnostics and therapeutics in renal cell and urothelial carcinomas. Dr. Wulff-Burchfield discussed strategies ...
UroToday6h
ASCO 2025: Functional Imaging in Renal Cell Carcinoma: Enhancing Diagnosis and Treatment Strategies
Annual Meeting held in Chicago, IL, was host to a State of the Science session on novel diagnostics and therapeutics in renal cell and urothelial carcinomas. Dr. Michael Hofman presented an in-depth ...
UroToday23h
ASCO 2025: FGFR3 Alteration Status and Outcomes with Immune Checkpoint Inhibitors in Patients with Metastatic Urothelial Carcinoma
ASCO annual meeting featured a urothelial carcinoma session and a presentation by Dr. Shilpa Gupta discussing FGFR3 alteration status and outcomes with immune checkpoint inhibitors in patients with ...
UroToday19h
AUA 2025: The First Report of Disease-Free Survival Analyses from the NIAGARA Trial of Perioperative Durvalumab plus Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer
(UroToday.com) The American Urological Association's 2025 Annual Meeting, between April 26 – 29, 2025 in Las Vegas, Nevada, was host to the PD37: Bladder Cancer: Invasive III Session. Dr. Joshua Meeks ...
UroToday19h
AUA 2025: Rucaparib Versus Docetaxel or Second-Generation Androgen Receptor Pathway Inhibitor Therapy for Metastatic Castration-Resistant Prostate Cancer Patients with BRCA ...
(UroToday.com) The American Urologic Association (AUA) 2025 Annual Meeting held in Las Vegas, NV was host to an advanced prostate cancer moderated poster session. Dr. David Morris presented results ...